Dornase alfa for cystic fibrosis

Paediatr Respir Rev. 2017 Jan:21:65-67. doi: 10.1016/j.prrv.2016.09.001. Epub 2016 Sep 15.

Authors

C L Yang¹, M Chilvers², M Montgomery³, S J Nolan⁴

Affiliations

¹ British Columbia Children's Hospital, Department of Pediatrics, Division of Respiratory Medicine, Vancouver, BC, Canada. Electronic address: connie.yang@cw.bc.ca.
² British Columbia Children's Hospital, Department of Pediatrics, Division of Respiratory Medicine, Vancouver, BC, Canada.
³ Alberta Children's Hospital, Pediatrics and Child Health, Calgary, AB, Canada.
⁴ The University of Liverpool, Department of Biostatistics, Liverpool, UK.

PMID: 27769785
DOI: 10.1016/j.prrv.2016.09.001

No abstract available

Publication types

Review

MeSH terms

Cystic Fibrosis / drug therapy*
Cystic Fibrosis / mortality
Cystic Fibrosis / physiopathology
Deoxyribonuclease I / therapeutic use*
Disease Progression
Forced Expiratory Volume
Humans
Recombinant Proteins / therapeutic use

Substances

Recombinant Proteins
Deoxyribonuclease I
dornase alfa